Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies

References

• Ly TT, Maahs DM, Rewers A, et al. ISPAD clinical practice consensus guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(Suppl 20):180–192.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Cooper MN, Davis EA, Jones TW. Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents. Diabet Med. 2013;30:1126–1131. doi:10.1111/dme.12247
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
   PubMed Web of Science ®Google Scholar
• Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017;9:320–324. doi:10.1111/1753-0407.12524
   PubMed Web of Science ®Google Scholar
• Nathan DM; Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16. doi:10.2337/dc13-2112
   PubMed Web of Science ®Google Scholar
• Rewers MJ, Pillay K, de Beaufort C, et al. ISPAD clinical practice consensus guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(Suppl 20):102–114. doi:10.1111/pedi.12190
   PubMed Web of Science ®Google Scholar
• Phelan H, Clapin H, Bruns L, et al. The Australasian Diabetes Data Network: first national audit of children and adolescents with type 1 diabetes. Med J Aust. 2017;206:121–125. doi:10.5694/mja16.00737
   PubMed Web of Science ®Google Scholar
• International Hypoglycaemia Study G. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38:1583–1591. doi:10.2337/dc15-0279
   PubMed Web of Science ®Google Scholar
• Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes. 1988;37:901–907. doi:10.2337/diab.37.7.901
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395. doi:10.2337/dc12-2480
   PubMed Web of Science ®Google Scholar
• Jones TW; Group IHGW. Defining relevant hypoglycemia measures in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2018;19:354–355. doi:10.1111/pedi.12600
   PubMed Web of Science ®Google Scholar
• International Hypoglycaemia Study G. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40:155–157. doi:10.2337/dc16-2215
   PubMed Web of Science ®Google Scholar
• Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–1249. doi:10.2337/diacare.28.5.1245
   PubMed Web of Science ®Google Scholar
• Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–E74. doi:10.1152/ajpendo.1991.260.1.E67
   PubMedGoogle Scholar
• Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79:777–781. doi:10.1172/JCI112884
   PubMed Web of Science ®Google Scholar
• Fredheim S, Johansen A, Thorsen SU, et al. Nationwide reduction in the frequency of severe hypoglycemia by half. Acta Diabetol. 2015;52:591–599. doi:10.1007/s00592-014-0697-5
   PubMed Web of Science ®Google Scholar
• Cooper MN, O’Connell SM, Davis EA, Jones TW. A population-based study of risk factors for severe hypoglycaemia in a contemporary cohort of childhood-onset type 1 diabetes. Diabetologia. 2013;56:2164–2170. doi:10.1007/s00125-013-2982-1
   PubMed Web of Science ®Google Scholar
• Johansen A, Kanijo B, Fredheim S, et al. Prevalence and predictors of severe hypoglycemia in Danish children and adolescents with diabetes. Pediatr Diabetes. 2015;16:354–360. doi:10.1111/pedi.12171
   PubMed Web of Science ®Google Scholar
• Karges B, Rosenbauer J, Kapellen T, et al. Hemoglobin A1c Levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012. PLoS Med. 2014;11:e1001742. doi:10.1371/journal.pmed.1001742
   PubMed Web of Science ®Google Scholar
• Katz ML, Volkening LK, Anderson BJ, Laffel LM. Contemporary rates of severe hypoglycaemia in youth with type 1 diabetes: variability by insulin regimen. Diabet Med. 2012;29:926–932. doi:10.1111/j.1464-5491.2012.03646.x
   PubMed Web of Science ®Google Scholar
• Svoren BM, Volkening LK, Butler DA, Moreland EC, Anderson BJ, Laffel LM. Temporal trends in the treatment of pediatric type 1 diabetes and impact on acute outcomes. J Pediatr. 2007;150:279–285. doi:10.1016/j.jpeds.2006.12.009
   PubMed Web of Science ®Google Scholar
• Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10:711–722. doi:10.1038/nrendo.2014.170
   PubMed Web of Science ®Google Scholar
• Group UKHS. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147. doi:10.1007/s00125-007-0599-y
   PubMed Web of Science ®Google Scholar
• Hypoglycemia in the Diabetes Control and Complications Trial. The diabetes control and complications trial research group. Diabetes. 1997;46:271–286. doi:10.2337/diab.46.2.271
   PubMed Web of Science ®Google Scholar
• Bulsara MK, Holman CD, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care. 2004;27:2293–2298. doi:10.2337/diacare.27.10.2293
   PubMed Web of Science ®Google Scholar
• Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA. 2002;287:2511–2518. doi:10.1001/jama.287.19.2511
   PubMed Web of Science ®Google Scholar
• Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care. 1997;20:22–25. doi:10.2337/diacare.20.1.22
   PubMed Web of Science ®Google Scholar
• Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care. 1997;20:714–720. doi:10.2337/diacare.20.5.714
   PubMed Web of Science ®Google Scholar
• Karges B, Kapellen T, Wagner VM, et al. Glycated hemoglobin A1c as a risk factor for severe hypoglycemia in pediatric type 1 diabetes. Pediatr Diabetes. 2017;18:51–58. doi:10.1111/pedi.12348
   PubMed Web of Science ®Google Scholar
• O’Connell SM, Cooper MN, Bulsara MK, Davis EA, Jones TW. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000–2009. Diabetes Care. 2011;34:2379–2380. doi:10.2337/dc11-0748
   PubMed Web of Science ®Google Scholar
• Rosenbauer J, Dost A, Karges B, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care. 2012;35:80–86. doi:10.2337/dc11-0993
   PubMed Web of Science ®Google Scholar
• Tsalikian E, Tamborlane W, Xing D, et al.; Diabetes Research in Children Network Study G. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care. 2009;32:1954–1959.
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169–3176. doi:10.2337/db08-1084
   PubMed Web of Science ®Google Scholar
• Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–372. doi:10.1056/NEJMra1215228
   PubMed Web of Science ®Google Scholar
• Bottini P, Boschetti E, Pampanelli S, et al. Contribution of autonomic neuropathy to reduced plasma Adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect. Diabetes. 1997;46:814–823. doi:10.2337/diab.46.5.814
   PubMed Web of Science ®Google Scholar
• Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care. 1998;21:1960–1966. doi:10.2337/diacare.21.11.1960
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819–828. doi:10.1172/JCI116302
   PubMed Web of Science ®Google Scholar
• Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724–733. doi:10.2337/diabetes.51.3.724
   PubMed Web of Science ®Google Scholar
• Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness. Endocrinol Metab Clin North Am. 1999;28(495–500):v–vi. doi:10.1016/S0889-8529(05)70084-0
   Google Scholar
• Jones TW, Boulware SD, Kraemer DT, Caprio S, Sherwin RS, Tamborlane WV. Independent effects of youth and poor diabetes control on responses to hypoglycemia in children. Diabetes. 1991;40:358–363. doi:10.2337/diab.40.3.358
   PubMed Web of Science ®Google Scholar
• Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med. 1988;318:1487–1492. doi:10.1056/NEJM198806093182302
   PubMed Web of Science ®Google Scholar
• Hepburn DA, Patrick AW, Brash HM, Thomson I, Frier BM. Hypoglycaemia unawareness in type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabet Med. 1991;8:934–945. doi:10.1111/j.1464-5491.1991.tb01533.x
   PubMed Web of Science ®Google Scholar
• Jones TW, Borg WP, Borg MA, et al. Resistance to neuroglycopenia: an adaptive response during intensive insulin treatment of diabetes. J Clin Endocrinol Metab. 1997;82:1713–1718. doi:10.1210/jcem.82.6.3993
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Gold AE, Deary IJ, Kelnar CJ, Frier BM. Symptoms of hypoglycemia in children with IDDM. Diabetes Care. 1995;18:858–861. doi:10.2337/diacare.18.6.858
   PubMed Web of Science ®Google Scholar
• Tupola S, Rajantie J. Documented symptomatic hypoglycaemia in children and adolescents using multiple daily insulin injection therapy. Diabet Med. 1998;15:492–496. doi:10.1002/(SICI)1096-9136(199806)15:6<492::AID-DIA600>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283–287. doi:10.1016/S0140-6736(94)91336-6
   PubMed Web of Science ®Google Scholar
• van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4:893–902. doi:10.1016/S2213-8587(16)30193-0
   PubMed Web of Science ®Google Scholar
• Abraham MB, Nicholas JA, Smith GJ, et al. Reduction in hypoglycemia with the predictive low-glucose management system: a long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes Care. 2018;41:303–310. doi:10.2337/dc17-1604
   PubMed Web of Science ®Google Scholar
• Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240–1247. doi:10.1001/jama.2013.277818
   PubMed Web of Science ®Google Scholar
• Muche EA, Mekonen BT. Hypoglycemia prevention practice and its associated factors among diabetes patients at university teaching hospital in Ethiopia: cross-sectional study. PLoS One. 2020;15:e0238094. doi:10.1371/journal.pone.0238094
   PubMed Web of Science ®Google Scholar
• 13 Children and Adolescents. Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42:S148–S164. doi:10.2337/dc19-S013
   PubMedGoogle Scholar
• Evans Kreider K, Pereira K, Padilla BI. Practical approaches to diagnosing, treating and preventing hypoglycemia in diabetes. Diabetes Ther. 2017;8:1427–1435. doi:10.1007/s13300-017-0325-9
   PubMed Web of Science ®Google Scholar
• Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3–S13. doi:10.1089/dia.2015.0417
   PubMed Web of Science ®Google Scholar
• Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367–1377. doi:10.1016/S0140-6736(18)30297-6
   PubMed Web of Science ®Google Scholar
• Daniels J, Herrero P, Georgiou P. A deep learning framework for automatic meal detection and estimation in artificial pancreas systems. Sensors. 2022;22(2):466. doi:10.3390/s22020466
   PubMed Web of Science ®Google Scholar
• Iacobucci G. All patients with type 1 diabetes in England should be offered continuous glucose monitoring, says NICE. BMJ. 2022;376:o834. doi:10.1136/bmj.o834
   PubMedGoogle Scholar
• Stone JY, Bailey TS. Benefits and limitations of continuous glucose monitoring in type 1 diabetes. Expert Rev Endocrinol Metab. 2020;15:41–49. doi:10.1080/17446651.2020.1706482
   PubMed Web of Science ®Google Scholar
• Cook CA, Vakayil V, Pribyl K, et al. A pharmacist-driven glycemic control protocol to reduce the rate of severe hypoglycemia in high-risk patients. Hosp Pharm. 2022;57:45–51. doi:10.1177/0018578720973891
   PubMed Web of Science ®Google Scholar
• Przezak A, Bielka W, Molęda P. Fear of hypoglycemia-An underestimated problem. Brain Behav. 2022;12:e2633. doi:10.1002/brb3.2633
   PubMed Web of Science ®Google Scholar
• Maclean RH, Jacob P, Choudhary P, et al. Hypoglycemia subtypes in type 1 diabetes: an exploration of the hypoglycemia fear survey-II. Diabetes Care. 2022;45:538–546. doi:10.2337/dc21-1120
   PubMed Web of Science ®Google Scholar
• Kłak A, Mańczak M, Owoc J, Olszewski R. Can continuous glucose monitoring technology reduce fear of hypoglycemia in people with type 1 diabetes? Authors’ reply. Pol Arch Intern Med. 2022;132:16210.
   PubMedGoogle Scholar
• American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S61–S70. doi:10.2337/dc19-S006
   PubMed Web of Science ®Google Scholar
• Davis HA, Spanakis EK, Cryer PE, et al. Hypoglycemia during therapy of diabetes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2022, MDText.com, Inc; 2000.
   Google Scholar
• Forțofoiu M, Vladu IM, Forțofoiu MC, et al. New strategies of diagnostic and therapeutic approach to emergencies in the evolution of patients with diabetes mellitus (Review). Exp Ther Med. 2022;23:178. doi:10.3892/etm.2021.11101
   PubMed Web of Science ®Google Scholar
• De Buck E, Borra V, Carlson JN, Zideman DA, Singletary EM, Djärv T. First aid glucose administration routes for symptomatic hypoglycaemia. Cochrane Database Syst Rev. 2019;4:Cd013283. doi:10.1002/14651858.CD013283.pub2
   PubMedGoogle Scholar
• Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–232. doi:10.1056/NEJMoa1303576
   PubMed Web of Science ®Google Scholar
• Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. Cmaj. 2013;185:297–305. doi:10.1503/cmaj.121265
   PubMed Web of Science ®Google Scholar
• Boscari F, Ferretto S, Cavallin F, Fadini GP, Avogaro A, Bruttomesso D. Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care. Acta Diabetol. 2022;59:921–928. doi:10.1007/s00592-022-01884-1
   PubMed Web of Science ®Google Scholar
• Parcerisas A, Contreras I, Delecourt A, et al. A machine learning approach to minimize nocturnal hypoglycemic events in type 1 diabetic patients under multiple doses of insulin. Sensors. 2022;22(4):1665. doi:10.3390/s22041665
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J. 1983;287:462–463. doi:10.1136/bmj.287.6390.462-a
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Ceriani V. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality? Diabetes Obes Metab. 2018;20:1812–1816. doi:10.1111/dom.13317
   PubMed Web of Science ®Google Scholar
• Osumili B, Artime E, Mitchell B, et al. Cost of severe hypoglycemia and budget impact with nasal glucagon in patients with diabetes in Spain. Diabetes Ther. 2022;13:775–794. doi:10.1007/s13300-022-01238-8
   PubMedGoogle Scholar
• Pontiroli AE, Tagliabue E. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis. Acta Diabetol. 2020;57:743–749. doi:10.1007/s00592-020-01483-y
   PubMed Web of Science ®Google Scholar
• Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21:522–530. doi:10.1089/dia.2019.0148
   PubMed Web of Science ®Google Scholar
• Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon-A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care. 2021;44:1361–1367. doi:10.2337/dc20-2995
   PubMed Web of Science ®Google Scholar
• Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41:531–537. doi:10.2337/dc17-1402
   PubMed Web of Science ®Google Scholar
• Laugesen C, Ranjan AG, Schmidt S, Nørgaard K. Low-dose dasiglucagon versus oral glucose for prevention of insulin-induced hypoglycemia in people with type 1 diabetes: a phase 2, randomized, three-arm crossover study. Diabetes Care. 2022;45:1391–1399. doi:10.2337/dc21-2304
   PubMed Web of Science ®Google Scholar
• Battelino T, Tehranchi R, Bailey T, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021;22:734–741. doi:10.1111/pedi.13220
   PubMed Web of Science ®Google Scholar
• Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24:643–645. doi:10.2337/diacare.24.4.643
   PubMed Web of Science ®Google Scholar
• Haymond MW, DuBose SN, Rickels MR, et al. Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes. J Clin Endocrinol Metab. 2017;102:2994–3001. doi:10.1210/jc.2017-00591
   PubMed Web of Science ®Google Scholar
• Algeffari M, Hussain S, Almogbel T, Alsharidah M, Alghadouni H, Mahmood F. Home use of mini-dose glucagon as a novel treatment for hypoglycemia following repeated, prolonged fasts in type 1 diabetes during ramadan. Diabetes Care. 2022;45:990–993. doi:10.2337/dc21-1655
   PubMed Web of Science ®Google Scholar
• Rickels MR, DuBose SN, Toschi E, et al. Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care. 2018;41:1909–1916. doi:10.2337/dc18-0051
   PubMed Web of Science ®Google Scholar
• Karimian N, Qin T, Liang T, et al. Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats. Diabetes. 2013;62:2968–2977. doi:10.2337/db13-0164
   PubMed Web of Science ®Google Scholar
• Yue JT, Burdett E, Coy DH, Giacca A, Efendic S, Vranic M. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes. 2012;61:197–207. doi:10.2337/db11-0690
   PubMed Web of Science ®Google Scholar
• Yue JT, Riddell MC, Burdett E, Coy DH, Efendic S, Vranic M. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes. 2013;62:2215–2222. doi:10.2337/db12-1523
   PubMed Web of Science ®Google Scholar
• Farhat R, Aiken J, D’Souza NC, et al. ZT-01: a novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes. Diabetes Obes Metab. 2022;24:908–917. doi:10.1111/dom.14652
   PubMed Web of Science ®Google Scholar